Bullish
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
Barclays initiated coverage on SAB Biotherapeutics Inc. (SABS) with an Overweight rating and a $13 price target, projecting over 235% upside. Analyst ...